iBio, Inc. (NASDAQ:IBIO) Stock Has Average Target Price of $6.00 According to Analysts

iBio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts have a consensus “Buy” rating on iBio, based on seven brokerages: four rate it Buy, two Strong Buy, and one Sell. Their average 12-month price target is $6.00, including HC Wainwright’s $7.00 target.
  • Shares opened at $0.71, down 3.4% in the report, and are near their 12-month low of $0.68; the stock’s 12-month high is $3.82.
  • iBio reported quarterly EPS of -$0.05, better than the -$0.07 analyst consensus, and revenue of $1.07 million versus estimates of $0.03 million. The company is focused on AI-enabled drug discovery, including programs in obesity, metabolic disease, and oncology.
  • Five stocks to consider instead of iBio.

Shares of iBio, Inc. (NASDAQ:IBIO - Get Free Report) have been assigned a consensus rating of "Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $6.00.

IBIO has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of iBio from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright initiated coverage on iBio in a research report on Thursday, September 17th. They issued a "buy" rating and a $7.00 price target on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of iBio in a research note on Monday, September 21st.

Check Out Our Latest Analysis on IBIO

iBio Stock Down 3.4%

NASDAQ:IBIO opened at $0.71 on Tuesday. iBio has a 12 month low of $0.68 and a 12 month high of $3.82. The firm has a market cap of $49.79 million, a price-to-earnings ratio of -2.52 and a beta of 1.47. The company's 50 day moving average is $0.97 and its 200-day moving average is $1.62.

iBio (NASDAQ:IBIO - Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $0.03 million. Research analysts predict that iBio will post -0.35 EPS for the current fiscal year.

Institutional Trading of iBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in iBio in the 3rd quarter worth approximately $29,000. Headlands Technologies LLC grew its position in iBio by 333.0% during the second quarter. Headlands Technologies LLC now owns 47,413 shares of the company's stock worth $83,000 after buying an additional 36,463 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in iBio by 15.9% during the first quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company's stock valued at $893,000 after acquiring an additional 64,347 shares during the period. Landscape Capital Management L.L.C. bought a new position in iBio during the third quarter valued at about $105,000. Finally, Bank of America Corp DE raised its holdings in iBio by 150.8% in the 1st quarter. Bank of America Corp DE now owns 290,413 shares of the company's stock valued at $552,000 after acquiring an additional 174,620 shares in the last quarter. Institutional investors and hedge funds own 7.90% of the company's stock.

About iBio

(Get Free Report)

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company's current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.

Further Reading

Analyst Recommendations for iBio (NASDAQ:IBIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in iBio Right Now?

Before you consider iBio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iBio wasn't on the list.

While iBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines